Presentation is loading. Please wait.

Presentation is loading. Please wait.

The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter.

Published byOphelia Tyler Modified over 9 years ago

Similar presentations

Presentation on theme: "The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter."— Presentation transcript:

1 The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework Gunter von Minckwitz

2 Dra. María del Rosario Vidal Jefa del Servicio de Oncología Clínica del Hospital de Morón Estudio ICE Fase III: Ibandronato Adyuvante con o sin Capecitabina en Pacientes ancianas con cáncer de mama temprano con riesgo moderado o alto (GBG32, BIG 4-04) Gunter von Minckwitz, Toralf Reimer, Jochem Potenberg, Bettina Conrad, Heiko Graf, Holger Eidtmann, Marianne Just, Stephan Paepke, Elmar Stickeler, Georg Heinrich, Michael Untch, Volker Möbus, Christoph Thomssen, Christian Jackisch, Jens Huober, Sibylle Loibl, Valentina Nekljudova, Ulrike Nitz for the GBG / AGO-B / NOGGO / WSG study groups within the BIG framework

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

Download ppt "The phase III ICE study: Adjudiscloseant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer Gunter."

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Miles D et al. Proc SABCS 2012;Abstract P
Dr Antonio C. Buzaid Chefe Geral Centro Avançado de Oncologia

Dr Antonio C. Buzaid Chefe Geral Centro Avançado de Oncologia
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Xeloda X-panding options in the adjuvant treatment of breast cancer

Xeloda X-panding options in the adjuvant treatment of breast cancer
Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama

Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.

Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple.
Rosario García Campelo Servicio de Oncología Médica

Rosario García Campelo Servicio de Oncología Médica
PRESUPUESTO ASIGNADO POLICÍA NACIONAL VIGENCIA 2012 (GESTIÓN GENERAL) Cifras en millones RECURSO 10: RECURSOS CORRIENTES RECURSO 16: FONDOS ESPECIALES.

PRESUPUESTO ASIGNADO POLICÍA NACIONAL VIGENCIA 2012 (GESTIÓN GENERAL) Cifras en millones RECURSO 10: RECURSOS CORRIENTES RECURSO 16: FONDOS ESPECIALES.
1/03/09 De 89 à 98. 1/03/09 De 89 à 98 1/03/09 De 89 à 98.

1/03/09 De 89 à 98. 1/03/09 De 89 à 98 1/03/09 De 89 à 98.
OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT

OPEN ISSUES IN MULTIDISCIPLINARY BREAST CANCER MANAGEMENT
© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.

© 2013 RNA Diagnostics Inc. All rights reserved. Confidential 1 “RDA: better chemotherapy management” Investor Presentation April 2013.
Impact of Clinical Trials on Cancer Care in Low- and Middle – Income Countries Prof. Dra. Lucía Delgado Pebé Directora del Servicio de Oncología Clínica.

Impact of Clinical Trials on Cancer Care in Low- and Middle – Income Countries Prof. Dra. Lucía Delgado Pebé Directora del Servicio de Oncología Clínica.
Phase Difference = 0.00. Phase Difference = 0.05.

Phase Difference = Phase Difference = 0.05.
Key Issues in the Management of Metastatic Breast Cancer Case 2 (HER2 positive), v5 - July 3, 2009 - to Abraxis Medical.

Key Issues in the Management of Metastatic Breast Cancer Case 2 (HER2 positive), v5 - July 3, to Abraxis Medical.
Current situation of Clinical Research in Latin America International Clinical Trials Workshop FLASCA, ASCO, NCI, ONS. September, 11-13 2014. Córdoba,

Current situation of Clinical Research in Latin America International Clinical Trials Workshop FLASCA, ASCO, NCI, ONS. September, Córdoba,
75777981 81797775 83858789 89878583 91939597 97959391.

Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.

Targeting HER2 and Focusing on Patients With Gastric Cancer Jose Maria Vieitez, MD, PhD Assistant Professor of Oncology Department of Medical Oncology.
Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.

Extended duration of injection interval. 2 Lucas et al. Efficacy of lanreotide Autogel ® administered every 4–8 weeks in patients with acromegaly previously.
Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro A. Peccatori, Hatem A. Azim Jr., Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle C.

Matteo Lambertini, Marcello Ceppi, Francesca Poggio, Fedro A. Peccatori, Hatem A. Azim Jr., Donatella Ugolini, Paolo Pronzato, Sibylle Loibl, Halle C.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

Similar presentations

Ads by Google